The Academy has a profound duty to its members, the larger medical community and the public to ensure the integrity of all of its scientific, educational, advocacy and consumer information activities and materials. Thus each Academy Trustee, Secretary, committee Chair, committee member, taskforce chair, taskforce member, councilor, and representative to other organizations (“Academy Leader”), as well as the Academy staff and those responsible for organizing and presenting CME activities must disclose interactions with Companies and manage conflicts of interest or the appearance of conflicts of interest that affect this integrity. Where such conflicts or perceived conflicts exist, they must be appropriately and fully disclosed and resolved.
All contributors to Academy educational and leadership activities must disclose all financial relationships (defined below) to the Academy annually. The ACCME requires the Academy to disclose the following to participants prior to the activity:
- All financial relationships with Commercial Companies that contributors and their immediate family have had within the previous 12 months. A commercial company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
- Meeting presenters, authors, contributors or reviewers who report they have no known financial relationships to disclose.
The Academy will request disclosure information from meeting presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership activities (“Contributors”) annually. Disclosure information will be kept on file and used during the calendar year in which it was collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time of submission of a Journal article or materials for an educational activity or nomination to a leadership position, each Contributor should specifically review his/her statement on file and notify the Academy of any changes to his/her financial disclosures. These requirements apply to relationships that are in place at the time of or were in place 12 months preceding the presentation, publication submission, or nomination to a leadership position. Any financial relationship that may constitute a conflict of interest will be resolved prior to the delivery of the activity.
Financial Relationship Disclosure
For purposes of this disclosure, a known financial relationship is defined as any financial gain or expectancy of financial gain brought to the Contributor or the Contributor’s immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Contributor) by:
- Direct or indirect compensation;
- Ownership of stock in the producing company;
- Stock options and/or warrants in the producing company, even if they have not been exercised or they are not currently exercisable;
- Financial support or funding to the investigator, including research support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies; or
- Involvement with any for-profit corporation that is likely to become involved in activities directly impacting the Academy where the Contributor or the Contributor’s family is a director or recipient of a grant from said entity, including consultant fees, honoraria, and funded travel.
Description of Financial Interests
Consultant / Advisor |
C |
Consultant fee, paid advisory boards or fees for attending a meeting. |
Employee |
E |
Employed by or received a W2 from a commercial company. |
Lecture Fees |
L |
Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company. |
Equity / Stock Owner |
O |
Equity ownership/stock options in publicly or privately traded firms, excluding mutual funds. |
Patents / Royalty |
P |
Patents and/or royalties for intellectual property. |
Grant Support |
S |
Grant support or other financial support to the investigator from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. |
Secretary for Annual Meeting
Name |
Disclosure |
Maria M Aaron MD |
None |
Annual Meeting Program Committee
The Annual Meeting Program Committee is responsible for the Academy's annual meeting Scientific Program, including Instruction Courses, Symposia, the Spotlight on Cataract, Scientific Papers/ePosters and Videos. Each subcommittee has five - ten reviewers who grade the instruction courses and paper/e-poster abstracts as well as three subcommittee members who review the grades, then select the courses and abstracts for presentation.
Associate Secretary for the Annual Meeting Program |
Disclosure |
Bennie H Jeng MD |
EyeGate Pharmaceuticals Inc.: O; GlaxoSmithKline: C; Kedrion: C; Merck & Co., Inc.: C; Oyster point: C; Sanofi: C |
Annual Meeting Program Committee |
Nicole R Fram MD |
Alcon Laboratories, Inc.: C,L; Allergan: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,O,L; Dompé: C,L; Johnson & Johnson Vision: C; MicroSurgical Technology: L; Novartis Pharma AG: L; Ocular Science: O; Ocular Therapeutix: C,L |
Jessica B Ciralsky MD |
Bruder Healthcare Company: C; Johnson & Johnson Vision: C; Novartis, Alcon Pharmaceuticals: C |
Steven J Gedde MD |
None |
Andrew G Lee MD |
None |
Julian D. Perry, MD |
None |
Martha P Schatz MD |
None |
Elizabeth Yeu MD |
Alcon Laboratories, Inc.: C,L; Allergan: C,L; ArcScan: C; Bausch + Lomb: C; Bausch Lomb: C; Bio-Tissue, Inc.: C,L; Carl Zeiss Meditec: C,L; Glaukos Corporation: C,L; nnovation Labs: O; iOptics: C,S; Johnson & Johnson Vision: C,L; Kala: C,S; Katena Products, Inc: C; Melt: C,O; Modernizing Medicine: O; Novartis, Alcon Pharmaceuticals: C; Ocular Science: C,O; OcuSoft: C; Omeros: L; ScienceBased Health: C; Sight Sciences: C; Sun Ophthalmics: L; Surface: C; Tarsus: C,O; TearLab: C; TearScience: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S |
Sharon D Solomon MD |
None |
Subcommittee for: Cataract
Chair |
Disclosure |
Nicole R Fram MD |
Alcon Laboratories, Inc.: C,L; Allergan: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,O,L; Dompé: C,L; Johnson & Johnson Vision: C; MicroSurgical Technology: L; Novartis Pharma AG: L; Ocular Science: O; Ocular Therapeutix: C,L |
Subcommittee Members |
Surendra Basti MBBS |
Bausch + Lomb: C; Johnson & Johnson Vision: C |
Sathish Srinivasan MBBS |
Alcon Laboratories, Inc.: C; DORC International, bv/Dutch Ophthalmic, USA: C; Medicontur: C; Scope Ophthalmics: C; THEA: L; Zeiss: C |
Subcommittee Reviewers |
Brandon Ayres MD |
Alcon Laboratories, Inc.: C,L; Allergan: C,L; Bausch+Lomb: L; Carl Zeiss Inc: C; CorneaGen: C; Dompe: C,L; Glaukos Corporation: C; New World Medical Inc: C; Novartis, Alcon Pharmaceuticals: C; omeros: C; Sun Ophthalmics: C,L; Tear Lab: C |
Kourtney A Houser MD |
Alcon: L; Bausch and Lomb: C; Novartis, Alcon Pharmaceuticals: C |
Sumitra S Khandelwal MD |
Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Dompe: C; Kala: C; Ocular Therapeutix: C; Omeros Corporation: C |
Jeremy Z Kieval MD |
Alcon Laboratories, Inc.: C; Dompe: C; Johnson & Johnson: C,L; Kala: C,L; Novartis Pharma AG: C; Ocular Therapeutix: C; Sun Ophthalmics: C; Takeda: C,L; Tarsus: C |
Steven M Naids MD |
Allergan, Inc.: C; Bausch + Lomb: L; Eyevance: C |
Subcommittee for: Cornea, External Disease
Chair |
Disclosure |
Jessica B Ciralsky MD |
Bruder Healthcare Company: C; Johnson & Johnson Vision: C; Novartis, Alcon Pharmaceuticals: C |
Subcommittee Members |
Jennifer Y Li MD |
None |
Elmer Y Tu MD |
Daiichi Sankyo: C; Dompe: C; Eversight: E,S; Eye Bank Association of America: S; GlaxoSmithKline: C; Oyster Point: C; Santen, Inc.: C |
Subcommittee Reviewers |
Vatinee Y Bunya MD |
Bausch + Lomb: S |
Asim V Farooq MD |
GlaxoSmithKline: C |
Marjan Farid MD |
Allergan: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C; CorneaGen: C; Dompe: C; Johnson & Johnson Vision: C; KALA: C; Novartis, Alcon Pharmaceuticals: C; Sun Ophthalmics: C; Tarsus: C; zeiss: C |
Anat Galor MD |
Allergan: C; Dompe: C; Novaliq: C; Novartis Pharma AG: C; Shire: C |
Jennifer R Rose-Nussbaumer MD |
None |
Subcommittee for: Glaucoma
Chair |
Disclosure |
Steven J Gedde MD |
None |
Members |
Paula Anne Newman-Casey MD |
Centers for Disease Control and Prevention: S; National Eye Institute: S |
Brian C Samuels MD PhD |
Heidelberg Engineering: S |
Subcommittee Reviewers |
Jenny Chen MD |
None |
John T Lind MD |
Heru: S; Nicox: S |
Catherine Q Sun MD |
National Eye Institute: S |
Sarah Van Tassel MD |
Abbvie: C; Aerie Pharmaceuticals, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Equinox: C; New World Medical Inc: C |
Luis E Vazquez MD |
None |
Subcommittee for: Neuro-Ophthalmology, Electronic Health Records/Information Technology, Ethics, General Medical, Global Ophthalmology, Medical Education, Ophthalmic History and Vision Rehabilitation
Chair |
Disclosure |
Andrew G Lee MD |
None |
Members |
John J Chen MD PHD |
Roche Diagnostics: C; UCB: C |
Julie Falardeau MD |
None |
Reviewers |
Shauna E Berry DO |
None |
Courtney E Francis MD |
None |
Susan M Ksiazek MD |
None |
Y Joyce Liao MD PhD |
None |
Nagham Al-Zubidi MD |
None |
Subcommittee for: Ocular Pathology, Oncology and Oculoplastics, Orbit
Chair |
Disclosure |
Julian D Perry |
None |
Members |
Jonathan W Kim MD |
None |
Sara T Wester MD |
Horizon Therapeutics: C |
Reviewers |
Malena M Amato MD |
None |
Anne Barmettler MD |
None |
Steven M Couch MD |
None |
Michael K Yoon MD |
None |
Kenya M Williams MD |
None |
Subcommittee for: Pediatric Ophthalmology, Strabismus
Chair |
Disclosure |
Martha P Schatz MD |
None |
Members |
Stacy L Pineles MD |
None |
Federico G Velez MD |
Luminopia: S; Nevakar: C; Novartis: C |
Reviewers |
Kara M Cavuoto MD |
None |
Sean P Donahue MD PhD |
Gensight: C; Olleyes: C |
Judith E Gurland MD |
None |
Tina Rutar MD |
Sydnexis: S, C |
Mitchell B Strominger MD |
None |
Subcommittee for: Refractive Surgery and Optics Refraction Contact Lenses
Chair |
Disclosure |
Elizabeth Yeu MD |
Alcon Laboratories, Inc.: C,L; Allergan: C,L; ArcScan: C; Bausch + Lomb: C; Bausch Lomb: C; Bio-Tissue, Inc.: C,L; Carl Zeiss Meditec: C,L; Glaukos Corporation: C,L; nnovation Labs: O; iOptics: C,S; Johnson & Johnson Vision: C,L; Kala: C,S; Katena Products, Inc: C; Melt: C,O; Modernizing Medicine: O; Novartis, Alcon Pharmaceuticals: C; Ocular Science: C,O; OcuSoft: C; Omeros: L; ScienceBased Health: C; Sight Sciences: C; Sun Ophthalmics: L; Surface: C; Tarsus: C,O; TearLab: C; TearScience: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S |
Members |
J Bradley Randleman MD |
None |
Edward E Manche MD |
Alcon Laboratories, Inc.: S; Allergan: S; Averdro: C,S; Best Doctors, Inc.: C; Carl Zeiss Inc: C,S; Guidepoint: C; Johnson & Johnson Vision: C,S; Novartis Pharma AG: S; Ocular Therapeutix: S; Placid0, INc: O; Presbia, Inc.: S; RxSight: O; Vacu-Site: O,P |
Reviewers |
Shamik Bafna MD |
AcuFocus, Inc.: C; Alcon Laboratories, Inc.: C; Beaver-Visitec International, Inc.: C; Carl Zeiss Meditec: C; CorneaGen: C; Ocular Therapeutix: S; RxSight: C; Sight Sciences, Inc.: C |
Brad E Kligman MD |
Dompe: S |
Kathryn Masselam Hatch MD |
Carl Zeiss Meditec: C; cxlo: C; EyePoint: C; EyeVance: C; Glaukos Corporation: C,O; Johnson & Johnson Vision: C; Sun Ophthalmics: C |
Jodhbir S Mehta MBBS PhD |
None |
Denise M Visco MD |
Bruder Healthcare Company: C; Carl Zeiss Inc: C,L; Cassini USA, Inc.: C; Eye Point Pharmaceuticals: C; LENSAR: C,L; Omeros: C,L; Sun Pharmaceuticals: C,L |
Subcommittee for: Retina, Vitreous and Uveitis, Intraocular Inflammation
Chair |
Disclosure |
Sharon D Solomon MD |
None |
Members |
Anita Agarwal MD |
None |
Sunir J Garg MD FACS |
Allergan, Inc.: S; apellis: S; Bausch+Lomb: C; Boehringer Ingelheim: C,S; Johnson & Johnson: C; Nexttech: O; NGM Bio: S; Regeneron Pharmaceuticals, Inc.: S |
Reviewers |
Yannis Mantas Paulus MD |
Hedgefog Research Inc: C; PhotoSonoX LLC: P,O |
Roomasa Channa MD |
None |
Jay K Chhablani MBBS |
Abbvie: L; Allergan, Inc.: L; Biogen Inc: C; Novartis Pharma AG: C; Salutaris: C |
Adam S Wenick MD |
GENENTECH: C |
Alice Zhang MD |
None |
Jennifer E Thorne MD PhD |
AbbVie: C; Allergan: S; Clearside: C; Gilead Sciences: C; National Eye Institute: S; Santen: C |
John A Gonzales MD |
National Eye Institute: S |
Muge R Kesen MD |
None |
Jaclyn L Kovach MD |
Novartis Pharma AG: L; Regeneron Pharmaceuticals, Inc.: L |
Thomas A Albini MD |
Abbvie: C; Allergan: C; Bausch+Lomb: C; Clearside: C; GENENTECH: C; Mallinckrodt: C; Novartis, Alcon Pharmaceuticals: C; pSividia: C; Santen, Inc.: C |
Special Projects Committee
The Special Projects Committee is responsible for developing programming and formats that cross subspecialties, as well as complement those that are submitted by members or societies.
Associate Secretary |
Disclosure |
Florentino E Palmon MD |
None |
Members |
Daniel H Chang MD |
AcuFocus, Inc.: S; Allergan: C,S,L; Carl Zeiss Meditec: C,L; Johnson & Johnson Vision: C,L,S; Omega Ophthalmics: C,O |
Laura B Enyedi MD |
Novartis: C |
Collin M McClelland MD |
Horizon Therapeutics: C |
Carolyn K Pan MD |
None |
Rachel K Sobel MD |
Guidepoint: C |
Kateki Vinod MD |
None |
Skills Transfer Advisory Committee
The Skills Transfer Advisory Committee is responsible for selecting the Skills Transfer courses and labs.
Associate Secretary |
Disclosure |
Michael L Savitt MD |
None |
Members |
Brock K Bakewell MD |
Acufocus: S; Johnson & Johnson Vision: S |
Cat Burkat MD FACS |
None |
Clara C Chan MD |
Aequus: C; Allergan, Inc.: C,L,S; Bausch + Lomb: L,S; Johnson & Johnson Vision: C; Labtician Ophthalmics, Inc.: C; Novartis Pharma AG: C,S; Santen, Inc.: C; Sun Ophthalmics: C; TearLab Corporation: S; THEA: C,L; zeiss: C |
Brian A Francis MD |
None |
Anjali Tannan MD |
None |
Keye L Wong MD |
None |
2021 Subspecialty Day Advisory Committee
Associate Secretary |
Disclosure |
R Michael Siatkowski MD |
National Eye Institute: S; OMIC-Ophthalmic Mutual Insurance Company: C |
Members |
Bonnie An Henderson MD |
Alcon Laboratories, Inc.: C,L |
Michael S Lee MD |
horizon: O; springer: P; sun biopharma: C; uptodate: P |
Jennifer Irene Lim MD |
Aldeyra Therapeutics: S; Allergan, Inc.: C; Aura Biosciences: C; Chengdu Kanghong: S; Cognition Therapeutics: C; CRC Press/ Taylor and Francis: P; Eyenuk: C; GENENTECH: C,S; Greybug: S; Iveric Bio: C; JAMA Ophthalmology Editorial Board: C; Luxa: C; NGM: S; Novartis Pharma AG: C; Ophthea: C; Quark: C; Regeneron Pharmaceuticals, Inc.: C,S; Santen, Inc.: C; Stealth: S; Unity: C; Viridian: C |
Shahzad I Mian MD |
Centrasight: S; Kowa American Corporation: S; National Eye Institute: S |
Jody R Piltz MD |
Aerie Pharaceuticals: C,L,S |
2021 Subspecialty Day Program Directors
Cornea
Sophie X Deng MD PhD |
California Institute for Regenerative Medicine: S; Claris Biotherapeutics: C; Dompe Inc: C; Kowa Research Institute, Inc: C; National Eye Institute: S |
Vishal Jhanji MD |
None |
Sonal S Tuli MD |
None |
Glaucoma
Brian A Francis MD |
None |
Kelly Walton Muir MD |
None |
Neuro-Ophthalmology
Prem S Subramanian MD PhD |
GenSight Biologics: C,S; Horizon Pharmaceuticals: C,S; Invex Therapeutics: C; Santhera Pharmaceuticals: S; Viridian Therapeutics: C |
Peter A Quiros MD |
None |
Oculofacial Plastic Surgery
Catherine J Hwang MD |
None |
Thomas Edward Johnson MD |
None |
Pediatric Ophthalmology
David K Wallace MD MPH |
National Eye Institute: S |
Gena Heidary MD |
National Eye Institute: S |
Refractive Surgery
Burkhard Dick MD |
Avedro, Inc.: C; Bausch + Lomb: L; Johnson & Johnson Vision: C; Johnson & Johnson: L; Oculus Surgical, Inc.: P; RxSight Inc.: C |
Deepinder K Dhaliwal MD |
Allergan, Inc.: C; Avedro, Inc.: S; Haag-Streit Group: C; Horizon: C; Johnson & Johnson: C; Novartis: C,S; Noveome: S; Ocular Therapeutix: L,C; STAAR Surgical: L; Trefoil: C |
Retina
Mark W Johnson MD |
Amgen: C; Apellis: S; Aura Biosciences: C; Pfizer, Inc.: C |
Srinivas R Sadda MD |
4DMT: C; Allergan: C; Amgen: C; Apellis: C; Astellas: C; Bayer Healthcare Pharmaceuticals: C; Carl Zeiss Meditec: C,L,S; Centervue: C; GENENTECH: C; Heidelberg Engineering: C,L,S; Iveric bio: C; Merck & Co., Inc.: C; Nidek: L; Novartis Pharma AG: C,L; Optos, Inc.: C; oxurion: C; Regeneron Pharmaceuticals, Inc.: C; Topcon Medical Systems Inc.: L |
AAOE Content Committee
The AAOE Annual Meeting Program Committee is responsible for selecting the AAOE Instruction Courses, Coding Sessions and the Practice Management Master Classes.
Chair |
Disclosure |
Natalie M Loyacano COMT ROUB OSA OCSR (F)ATPO |
None |
Members |
Stephanie Mangham Collins MBA COA OCSR |
Regeneron Pharmaceuticals, Inc.: C,L |
Lovell Davis MHA CPC CPB CRCS |
None |
Tori Elkins COT MBA |
None |
Brett D Gerwin MD |
None |
Anthony Pruett Johnson MD FACS |
None |
Bansari Mehta MHA |
None |
Christine M McDonald COE COA ROUB OSC CTC OCS |
None |
Heather Modjesky COE |
None |
Academy Staff
Name |
Disclosure |
Debra Rosencrance |
None |
Melanie Rafaty |
None |
Sangeeta Fernandes |
None |
Susan Oslar |
None |
Ann L'Estrange |
None |
Elizabeth Washburn |
None |
Licia Wells |
None |
Julia Fennell |
None |
Sadie Peckens |
None |